CTLA4 and cancer: Several cancer types can be effectively treated with immune checkpoint inhibitors (ICIs), which are antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed death 1 (PD-1) [1,2,3,4,5].